China's HighLight to exit US-based biotech player Bonti
Chinese healthcare-focused GP HighLight Capital is set to exit its position in US-based biotechnology company Bonti after Allergan agreed to acquire the business for $195 million, plus additional payments if certain development targets are met.
HighLight first backed Bonti in early 2017, leading the extension to a Series B round worth $11.7 million in total. It then led a $15.5 million Series C at the beginning of this year. The company already...
More on Greater China
Latest News
Portfolio: Capital Square Partners and Aegis/StarTek
Capital Square Partners’ acquisition of Indian business processing outsourcing (BPO) player Aegis ultimately helped two different companies find global relevance after a turbulent and disruptive decade
Indian fintech Juspay raises $21m Series B
Juspay, a developer of mobile payment solutions for online businesses, has raised $21.6 million in a Series B round led by Vostok Emerging Finance, a Swedish investment firm.
Japan mobile banking player gets $45m Series C
Kyash, a Tokyo-based mobile banking start-up, has received $45 million in Series C funding led by Greenspring Associates and Goodwater Capital.
Square Peg joins Series B for Singapore's Doctor Anywhere
Australian VC firm Square Peg Capital has joined a $27 million Series B round for Singapore-based healthcare technology provider Doctor Anywhere.